An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.
Brabus Launches ‘Deep Blue’ G-Wagon, Speedboat & Luxury Watch Line
Brabus is unifying its collaborations with Mercedes-AMG, Finland’s Axopar Boats, and Panerai luxury watches under one Deep Blue collection.Being that Brabus is...
